BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 23093563)

  • 1. Origins of medical innovation: the case of coronary artery stents.
    Xu S; Avorn J; Kesselheim AS
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):743-9. PubMed ID: 23093563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicians' contributions to the development of coronary artery stents: a qualitative study of transformative device innovation.
    Kesselheim AS; Xu S; Avorn J
    PLoS One; 2014; 9(2):e88664. PubMed ID: 24533133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of inventiveness among Society of Interventional Radiology members and the impact of their social networks.
    Murphy KJ; Elias G; Jaffer H; Mandani R
    J Vasc Interv Radiol; 2013 Jul; 24(7):931-7. PubMed ID: 23796080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 40 Years of Percutaneous Coronary Intervention: A Historical Remark on the Development and Evolution of Guidewire Technology.
    Kaltenbach M
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2582-2583. PubMed ID: 29268889
    [No Abstract]   [Full Text] [Related]  

  • 5. Introducing new contraceptives.
    Segal SJ; Coutinho E
    Draper Fund Rep; 1986 Dec; (15):27-32. PubMed ID: 12341234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
    Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
    Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Out of the Mind of Edward B. Diethrich: The Development of the Polytetrafluoroethylene-Covered Coronary Stent.
    Patel NJ; Agasthi P; Mhatre AU; Heuser RR
    J Endovasc Ther; 2020 Feb; 27(1):157-159. PubMed ID: 31735115
    [No Abstract]   [Full Text] [Related]  

  • 8. How Did Andreas Get Here?
    King SB
    JACC Cardiovasc Interv; 2015 Oct; 8(12):1645-6. PubMed ID: 26493260
    [No Abstract]   [Full Text] [Related]  

  • 9. Sources of innovation: an assessment of intellectual property.
    Kinch MS; Raffo J
    Drug Discov Today; 2015 May; 20(5):500-4. PubMed ID: 25499663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An examination of nurse-authored patents: Implications for nursing practice.
    Davis CR; Glasgow MES
    Nurs Forum; 2020 Nov; 55(4):772-781. PubMed ID: 32851679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue Vaccines: A Perspective from the Point of View of Intellectual Property.
    da Veiga CP; da Veiga CR; Del Corso JM; da Silva WV
    Int J Environ Res Public Health; 2015 Aug; 12(8):9454-74. PubMed ID: 26274968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New technologies aimed at percutaneous intervention in the small coronary artery.
    Bromage DI; Lim JC; Ramcharitar S
    Expert Rev Cardiovasc Ther; 2012 Apr; 10(4):441-55. PubMed ID: 22458578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Herbal drug patenting in India: IP potential.
    Sahoo N; Manchikanti P; Dey SH
    J Ethnopharmacol; 2011 Sep; 137(1):289-97. PubMed ID: 21640810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
    Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating the impact of public health notification: Duke clopidogrel experience.
    Eisenstein EL; Wojdyla D; Anstrom KJ; Brennan JM; Califf RM; Peterson ED; Douglas PS
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):767-74. PubMed ID: 23093562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting commercial success for Australian medical inventions patented in the United States: a cross sectional survey of Australian inventors.
    Mattes E; Stacey MC; Marinova D
    Med J Aust; 2006 Jan; 184(1):33-8. PubMed ID: 16398629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent.
    Waksman R; Pakala R
    EuroIntervention; 2009 Dec; 5 Suppl F():F36-42. PubMed ID: 22100674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Academic technology transfer and radiology: a strong partnership for the future.
    Eusemann CD; Sammons BE; Holmes DR; Brady TJ; Erenburg I; Toneguzzo F
    Acad Radiol; 2007 Nov; 14(11):1289-95. PubMed ID: 17964453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Origins of medical innovation: the case of coronary artery stents.
    Tomaselli GF
    Circ Cardiovasc Qual Outcomes; 2012 Nov; 5(6):741-2. PubMed ID: 23170004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.